Ever since Pauli' first recommended thiocyanates for the treatment of hypertension almost forty years ago, the therapeutic value of these drugs has been a subject of controversy. Interest apparently declined after Ayman's pronouncement,' in 1931, that thiocyanates lacked dinical usefulness because there appeared to be an insufficient margin of safety between the hypotensive and the toxic doses. Recently Barker2 applied a method for the determination of cyanates in blood and again revived interest in the thiocyanates by claiming that their effective therapeutic range lay in a blood serum content of from 8 to 12 mg. per cent of thiocyanate, while intoxication was not encountered until a serum level of 15 to 30 mg. had been reached. By means of this improved control over the administration of the drug, Barker avoided the hazards of intoxication and achieved gratifying symptomatic results and significant amelioration of hypertension in the majority of his patients.
Ever since Pauli' first recommended thiocyanates for the treatment of hypertension almost forty years ago, the therapeutic value of these drugs has been a subject of controversy. Interest apparently declined after Ayman's pronouncement,' in 1931, that thiocyanates lacked dinical usefulness because there appeared to be an insufficient margin of safety between the hypotensive and the toxic doses. Recently Barker2 applied a method for the determination of cyanates in blood and again revived interest in the thiocyanates by claiming that their effective therapeutic range lay in a blood serum content of from 8 to 12 mg. per cent of thiocyanate, while intoxication was not encountered until a serum level of 15 to 30 mg. had been reached. By means of this improved control over the administration of the drug, Barker avoided the hazards of intoxication and achieved gratifying symptomatic results and significant amelioration of hypertension in the majority of his patients.
The present study was stimulated by Barker's encouraging experience with his controlled method of treatment in a disease which has long eluded our therapeutic efforts.
Methods and frocedure Twenty patientst with pronounced arterial hypertension were taken at random from the wards and out-patient clinics of the New Haven Hospital and Dispensary. Although all of the individuals included in this study were known to have had hypertension for from one to ten years, nevertheless, a placebo of syrup of sarsaparilla or syrup of wild cherry was administered for several weeks or months while one of us obtained additional control bloodpressure readings and carried out other preliminary procedures. Each case t The original group contained eight additional patients who are not included in this study because they were either not sufficiently cooperative or they were not observed by us personally throughout the experimental period. study included a detailed anamnesis, general physical examination, description of the fundus oculi, roentgenographic studies of the heart, electrocardiograms, urinalyses, and determinations of the non-protein nitrogen of the blood. Pyelographic examinations were made when indicated, and early in the study the lability of the blood pressure in some of the patients was investigated by testing the response of the blood pressure to Periods of thiocyanate and placebo medication, usually of several months' duration, were alternated without the patient's knowledge of any change in therapy. This was facilitated by using either a 50 per cent syrup of sarsaparilla or syrup of wild cherry both as a placebo and as a vehicle whose excessive sweetness masked the taste of the thiocyanate when the drug was added.
Patients were asked to present themselves for follow-up examinations at intervals varying from one to four weeks, and at each visit a history of symptoms was recorded and the blood pressure was determined in the sitting position repeatedly at about five-minute intervals for at least half an hour or longer until several similar successive readings had been obtained. Each individual was usually seen by the same physician throughout the period of the experiment, and the blood-pressure readings were not divulged to the patient. Except for the administration of the potassium thiocyanate and its vehide, no other treatment or advice was given, and the patients were permitted to follow their customary mode of living. It was sought in this way to eliminate as far as possible the influence of psychic and extraneous factors on the blood pressure.
Results
We believe that the evaluation of any form of treatment for hypertension should be based primarily on a careful study of the effect of the therapy on the blood pressure, and these data, if published, should be offered in sufficient detail to permit an independent appraisal by the reader. Ideally, this requires the presentation of all the recorded blood-pressure readings on every patient during the entire period of the experiment. Symptomatic effects are admittedly both relevant and important observations, but they lack the objectivity and freedom from suggestion that characterize sphygmomanometric readings when the latter are-adequately observed. Our Four patients had no symptoms before, during, or after treatment. Eight patients probably felt improved during thiocyanate therapy, yet in four of these the hypertension was not overcome. In eight patients symptoms were not relieved, although in three of them the blood pressure fell appreciably but not to normal. Two of these patients felt worse; it is noteworthy that they were not subjects whose blood pressure had been markedly reduced. Several other patients also felt worse during part of the thiocyanate course, but, as will be indicated below, the increased symptoms coincided with excessive serum thiocyanate concentrations and are probably to be regarded as manifestations of intoxication.
It appears that symptomatic improvement is frequent but not the rule under thiocyanate therapy and the probability of improvement is greater if the blood pressure falls. It may occur in the absence of a hypotensive effect, and that some patients may feel worse even if the blood pressure has not been greatly altered. There is no evidence in these observations to support the view held by some that hypertensive patients feel less well if the blood pressure is lowered. Nor, incidentally, did we encounter any objective evidence of injury from the treatment, as indicated by the renal or cardiac functional status, eye grounds, and electrocardiograms in those patients whose hypertension was appreciably diminished. Dosage requirements: Although the "cyanating dose" could be calculated with relative accuracy when it was desired to bring the serum thiocyanate level quickly to a predetermined point (see Methods and procedure), the selection of continued doses to maintain this serum thiocyanate concentration proved to be a highly individual matter and usually required periodic readjustments of dose under the guidance of frequently repeated blood analyses during the first few weeks of the treatment. The average daily maintenance dose for the entire group of 20 patients approximated 0.5 gm. of potassium thiocyanate (3 teaspoonsful daily of a 4 per cent solution), but individual needs varied from 0.1 6 gm. to 0.64 gm. In general, patients with evidence of impaired renal function could be maintained at a given serum thiocyanate level with smaller daily doses than could patients with apparently normal renal function, but there may well be other contributing factors.
Inspection of Figs. 1 to 10 reveals that significant hypotensive effects, in the patients showing complete or partial alleviation of their hypertension, were observed occasionally at serum SCN levels as low as 4-and 6 mg. per cent, but that the optimal effects were most commonly associated with serum SCN concentrations of from 8 to 15 mg. per cent.
It has long been common practice, as in our out-patient dinic, to administer the thiocyanate salts in conventional doses of about 0.3 gmi. daily without an initial large "cyanating dose" and without control by blood analyses. We inquired briefly into the soundness of this procedure by choosing at random from the out-patient clinic ten patients who had been receiving the customary daily dose of 0.3 gm. of potassium thiocyanate for many weeks or several months. Blood analyses in seven patients revealed serum thiocyanate levels ranging from 1.9 to 3.5 mg. per cent; in three patients, all with evidence of renal functional impairment, the serum thiocyanate concentration was 12.4, 1 7.3, and 1 8.7 mg. per cent.
These observations indicate the importance of evaluating the patient's renal function before instituting thiocyanate therapy, and illustrate the necessity for determining the serum thiocyanate levels in regulating dosage if, on the one hand, an effective concentration of the drug is to be achieved and, on the other, hazardous cumulation is to be avoided.
Toxic effects: The manifestations that have been attributed to intoxication with thiocyanate salts are numerous and include, among others, such symptoms as lassitude, anorexia, nausea, vertigo, and weakness-symptoms which were common among our hypertensive patients in the absence of thiocyanate medication. We therefore regarded as probable evidence of intoxication only those symptoms which appeared for the first time in a given patient while thiocyanate was being administered and not dearly explained on another basis.
Judged in this broad manner, the following probably toxic effects were encountered: macular eruption with pruritis localized to back, once; anemia (perhaps the result of bleeding hemorrhoids), once; nausea, three times; diarrhea, twice; marked ulnar palsy, once; pain in jaws and teeth, twice; symptoms of upper respiratory infection, three times; pronounced lassitude and drowsiness, four times.
These presumably toxic manifestations were all associated with serum thiocyanate concentrations ranging between 15.7 and 21 mg. per cent, with the following striking exception:
Patient F. L. developed pain in the jaws and sensitiveness of the teeth to heat and cold after having taken potassium thiocyanate in a daily dose of 0.6 gm. for 14 days, at which time the concentration of the drug in the serum was but 6.6 mg. per cent. After two more weeks of continued treatment with the same dose, nausea and bloody diarrhea appeared. He did not present himself for examination at this time but discontinued his medication and subsequently recovered. Because we were not convinced that his symptoms were due to thiocyanate, and since it seemed important to establish definitely whether intoxication might occur on a relatively low serum thiocyanate level, we cautiously resumed therapy two months later. At the end of one week the pain in the jaws and temperature sensitivity of the teeth returned, together with nausea and lassitude; the serum thiocyanate level was 6.2 mg. per cent. We believe, therefore, that these symptoms were manifestations of intoxication at blood thiocyanate levels that are ordinarily considered non-toxic.2 Idiosyncrasy to thiocyanate may, of course, have been responsible.
The symptoms of pain in the jaws and temperature sensitivity of the teeth were encountered twice in this patient and in one other patient during thiocyanate medication. In the latter subject there was an associated severe ulnar palsy which disappeared promptly on the cessation of the medication and the simultaneous liberal administration of thiamin chloride parenterally; the patient's diet had appeared adequate and he was not an alcoholic. In the literature dealing with thiocyanate intoxication in man we have encountered no previous mention of these presumably neuritic manifestations.
Although, as indicated above, intoxication was common when the serum thiocyanate exceeded 15 mg. per cent, and apparently occurred on one occasion at a much lower level, there were numerous instances in which no untoward effects appeared in patients whose serum thiocyanate concentrations inadvertently rose on occasion to values ranging from 15 to 33 mg. per cent.
Criteria for the selection of patients Our group of 20 subjects is admittedly too small to yield criteria for the prediction of results unless the degree of correlation in one feature or another proves unusually high.
Age: The patients in this study ranged from 27 to 63 years in age. The age distribution, when grouped according to the degree of remission of the hypertension under thiocyanate therapy, was as follows: The most successfully treated group was also the youngest in average age, while the group of therapeutic failures was the oldest, but equally young individuals occurred at both extremes and the correlation of age with type of response was not uniform through the four groups. Relative youth was not, therefore, a guarantee of success, for only one of four patients below the age of 40 responded well.
Sex: The 20 subjects induded 13 females and 7 males. The sex distribution of the patients, when grouped according to the degree of therapeutic remission of the hypertension, was as follows: Evidently both sexes responded in about equal proportions. Duration of hypertension: If it is held that structural changes in the arterioles advance with increasing duration of hypertension, one might anticipate best therapeutic results in patients whose disease is still of relatively recent development. Examination of our results from this point of view revealed the following relationship between the known duration of hypertension and the therapeutic response: In Table 5 , which follows, the relation of the grades of hypertension to the varieties of therapeutic response to thiocyanate is shown. -I-II
The proportion of patients with moderate and severe hypertension was practically the same in the two groups showing a therapeutic response as in the two groups that did not. Apparently the presence of severe hypertension is not inimical to a satisfactory therapeutic remission. It is possible that patients with mild hypertension might have responded more uniformly with a complete remission of the hypertension, but our cases included only one in this classification and the results in this individual were not conclusive.
The presemwe of compllications: Although we excluded from increasing hypertensive retinitis. Since the severity of hypertensive disease is, in a sense, an expression of the extent of arteriolar abnormalities, it seemed interesting to compare the varieties of therapeutic response with the degree of associated retinitis in each group. This was done in Table 7 , which follows: There is no apparent correlation between the degree of retinitis and the blood-pressure response to thiocyanate. The fact that the group with the least abnormality showed only doubtful effect of the treatment on blood pressure is probably insignificant.
Cold pressor and txstrite tests: In ten patients an attempt was made to ascertain their vasomotor reactivity with the purpose of determining whether the positive demonstration of induced lability of the blood pressure would coincide with a favorable therapeutic response to thiocyanates and might serve, therefore, as a basis for the selection of cases. For this purpose the cold pressor test as described by Hines and Brown4 was used. This was usually supplemented by a "nitrite test," which consisted in the oral administration of 0.03 gm. of sodium nitrite every half hour until an appreciable lowering of blood pressure was manifested or until a maximum of six doses had been given. In a few patients the lability of the hypertension was studied by obtaining an hourly blood-pressure reading through a 24-hour period. No correlation was obvious between blood-pressure changes with these procedures and success or failure to respond to thiocyanate therapy.
We failed, therefore, to find any obvious clue which might prove helpful in predicting a favorable response to treatment. The data are, nevertheless, presented in the hope that they may contribute toward the accumulation of more abundant and adequate information from which criteria for the selection of patients may ultimately evolve.
Summary
Of 20 patients who were treated with potassium thiocyanate in large "controlled" doses, 10 manifested significant lowering of the blood pressure, with complete remission of hypertension in four.
Symptomatic improvement was about equally common but was not necessarily associated with relief from hypertension.
Optimal beneficial effects on blood pressure were most commonly noted when the serum SCN concentration ranged from 8 to 1 5 mg. per cent.
Toxic manifestations were common with serum SCN concentrations above 15 mg. per cent, but were not invariably present even with twice this concentration; on the other hand, serious intoxication was encountered with serum SCN concentrations of between 6 and 7 mg. per cent in one patient.
A rapid method of bringing the serum SCN concentration to any desired level is described. The estimation of maintenance doses of potassium thiocyanate proved to be a highly individual matter and required frequent quantitative determinations of serum SCN.
Toxic manifestations not generally attributed to thiocyanate included pain in the jaws, temperature sensitivity of the teeth, and ulnar palsy; these may all represent expressions of peripheral neuritis.
Examination of our data for criteria that might serve for the. selection of patients suitable for this form of therapy included considerations of age, sex, duration of hypertension, severity of hypertension, cardiac and renal complications, retinitis, and tests of vascular reactivity; none showed a sufficiently high correlation to appear useful. Conclusion Remission of hypertension and symptoms may be induced in some patients by the oral administration of potassium thiocyanate in relatively large doses, but the proper control of dosage requires repeated observations of the serum SCN concentrations.
